Frequently Asked Questions
The market is segmented based on , By Treatment (Medication, Desmopressin, Emicizumab, Anti-fibrinolytics, Factor Replacement Therapy, Desmopressin and Fibrin Sealants, Monoclonal Antibodies, ITI Therapy, Gene Therapy, Fibrin Sealants, and Others), Route of Administration (Oral, Injectable, and Others), Diagnosis (Blood Test, Genetic Tests, and Others), Patient (Pediatric, and Adult), Type (Haemophilia A, Haemophilia B, Haemophilia C, and Others), End-Users (Hospitals, Specialty Clinics, Homecare, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, and Others) – Industry Trends and Forecast to 2031.
.
The Global Haemophilia Market size was valued at USD 12.16 USD Billion in 2023.
The Global Haemophilia Market is projected to grow at a CAGR of 7.6% during the forecast period of 2024 to 2031.
The major players operating in the market include Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.), Novartis AG (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Sanofi (France), AstraZeneca (U.K.), Johnson & Johnson Private Limited (U.S.), Merck & Co. Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Baxter (U.S.), Takeda Pharmaceutical Company Limited (Japan), Grifols, S.A. (Spain), CSL (U.S.), BioMarin (U.S.), Spark Therapeutics, Inc. (U.S.), Chugai Pharmaceutical Co. Ltd. (Japan), Octapharma AG (Switzerland), Novo Nordisk A/S (Denmark), Biogen (U.S.), Genentech Inc. (U.S.), Bayer AG (Germany), Ferring B.V. (Switzerland).
The market report covers data from the U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, U.A.E., Egypt, Israel, Rest of the Middle East and Africa.
